NUVL: We expect GSK acquisition to go through; Downgrade to Market-Perform with PT matching deal price

Research evidence excerpt

NUVL: We expect GSK acquisition to go through; Downgrade to Market-Perform with PT matching deal price

ject the entities noted herein to any regulation or licensing requirement within such jurisdiction.

Source: Bloomberg Index Services Limited. BLOOMBERG® is a trademark and service mark of Bloomberg Finance L.P. and its

affiliates (collectively “Bloomberg”). Bloomberg or Bloomberg’s licensors own all proprietary rights in the Bloomberg Indices.

Neither Bloomberg nor Bloomberg’s licensors approves or endorses this material, or guarantees the accuracy or completeness of

any information herein, or makes any warranty, express or implied, as to the results to be obtained therefrom and, to the maximum

extent allowed by law, neither shall have any liability or responsibility for injury or damages arising in connection therewith.

No part of this material may be reproduced, distributed or transmitted or otherwise made available without prior consent of the

entities noted herein. Copyright Bernstein Institutional Services LLC Bernstein Autonomous LLP, BSG France S.A., Sanford C.

Bernstein (Hong Kong) Limited 盛博香港有限公司, Sanford C. Bernstein (Canada) Limited, Sanford C. Bernstein (India) Private

Limited (SEBI registration no. INH000006378), Sanford C. Bernstein (Singapore) Private Limited and Sanford C. Bernstein Japan

KK (サンフォード・C・バーンスタイン株式会社). All rights reserved. The trademarks and service marks contained herein are

the property of their respective owners. Any unauthorized use or disclosure is strictly prohibited. The entities noted herein may

pursue legal action if the unauthorized use results in any defamation and/or reputational risk to the entities noted herein and

research published under the Bernstein and Autonomous brands.

US SMID-CAP BIOPHARMACEUTICALS 14